Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 4 1

Status

Recruiting 8Completed 5Unknown 4Not yet recruiting 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Breast Neoplasms 6392Neoplasms 5365Prostatic Neoplasms 2966Carcinoma, Non-Small-Cell Lung 2709Colorectal Neoplasms 2679Lung Neoplasms 2267Multiple Myeloma 1663Lymphoma 1600Neoplasm Metastasis 1552Leukemia, Myeloid, Acute 1540Melanoma 1486Pancreatic Neoplasms 1470Ovarian Neoplasms 1423Leukemia 1389Head and Neck Neoplasms 1284Precursor Cell Lymphoblastic Leukemia-Lymphoma 1282Lymphoma, Non-Hodgkin 1231Colonic Neoplasms 1159Carcinoma, Hepatocellular 1142Stomach Neoplasms 1129Leukemia, Lymphocytic, Chronic, B-Cell 1090Brain Neoplasms 1050Rectal Neoplasms 980Lymphoma, Follicular 979Recurrence 976Uterine Cervical Neoplasms 926Glioblastoma 920Carcinoma, Renal Cell 882Lymphoma, Large B-Cell, Diffuse 853Hodgkin Disease 777

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1Topotecan 1SAR125844 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Malignant Solid Tumors × Clear all
NCT05930457 2023-12-26

Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

The First Affiliated Hospital of Guangzhou Medical University

Phase 1 Completed
15 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT05814835 2023-12-20

First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Chinese PLA General Hospital

Phase 1 Completed
14 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT02805166 2016-06-17

PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 4 Completed
420 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT01391533 2016-04-13

SARMET

Sanofi

Phase 1 Completed
72 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT00516438 2010-12-08

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

AstraZeneca

Phase 1 Completed
48 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡